Granted Patent B2

US 10,639,369 · App. 15/665,030 · Granted May 5, 2020

Inventors: W. Jason Cummings (Bellevue, WA); Gregory A. Demopulos (Mercer Island, WA); Thomas Dudler (Bellevue, WA); Larry W. Tjoelker (Kirkland, WA); Christi L. Wood (Snohomish, WA); Munehisa Yabuki (Seattle, WA)

Assignee: Omeros Corporation

A61K39/3955C07K16/40C12N9/6424C12Y304/21104A61K2039/505A61K2039/54A61K2039/545C07K2317/24C07K2317/33C07K2317/34C07K2317/565C07K2317/734C07K2317/76C07K2317/90C07K2317/92

Abstract

Claims (30)

1. An isolated antibody, or antigen-binding fragment thereof, that binds to MASP-3 comprising: a heavy chain variable region comprising a HC-CDR1 set forth as SEQ Id NO:84 (GKWIE); a HC-CDR2 set forth as SEQ ID NO:86 (EILPGTGSTNYNEKFKG) or SEQ ID NO:275 (EILPGTGSTNYAQKFQG); and a HC-CDR3 set forth as SEQ ID NO:88 (SEDV); and a light chain variable region comprising a LC-CDR1 set forth as SEQ ID NO: 142 (KSSQSLLNSRTRKNYLA), SEQ lD NO:257 (KSSQSLLQSRTRKNYLA); SEQ ID NO:258 (KSSQSLLASRTRKNYLA); or SEQ lD NO:259 (KSSQSLLNTRTRKNYLA), a LC-CDR2 set forth as SEQ ID NO: 144 (WASTRES); and a LC-CDR3 set forth as SEQ ID NO:161 (KQSYNIPT).

2. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:258.

3. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a murine antibody, and an antigen-binding fragment of any of the foregoing.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof is selected from the group consisting of a single chain antibody, an ScFv, a Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, a univalent antibody lacking a hinge region and a whole antibody.

5. The antibody or antigen-binding fragment thereof of claim 1 , further comprising an immunoglobulin constant region.

6. The antibody or antigen binding fragment thereof of claim 3 , wherein the antibody or antigen-binding fragment is humanized.

7. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody binds to the serine protease domain of human MASP-3 with an affinity of less than 500 pM.

8. The antibody or antigen-binding fragment thereof of 1 , wherein said antibody inhibits alternative pathway activation in mammalian blood.

9. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the HC-CDR2 comprises SEQ ID NO:86.

10. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the HC-CDR2 comprises SEQ ID NO:275.

11. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:142.

12. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:257.

13. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:259.

14. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the HC-CDR1 comprises SEQ ID NO:84, the HC-CDR2 comprises SEQ ID NO:86, the HC-CDR3 comprises SEQ ID NO:88, the LC-CDR1 comprises SEQ ID NO:258, the LC-CDR2 comprises SEQ ID NO:144 and the LC-CDR3 comprises SEQ ID NO:161.

15. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the HC-CDR1 comprises SEQ ID NO:84, the HC-CDR2 comprises SEQ ID NO:275, the HC-CDR3 comprises SEQ ID NO:88; the LC-CDR1 comprises SEQ ID NO:258, the LC-CDR2 comprises SEQ ID NO:144 and the LC-CDR3 comprises SEQ ID NO:161.

16. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:30.

17. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:45.

18. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:30 and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:45.

19. The isolated antibody or antigen-binding fragment thereof of claim 6 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:254.

20. The isolated antibody or antigen-binding fragment thereof of claim 6 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:255.

21. The isolated antibody or antigen-binding fragment thereof of claim 6 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:256.

22. The isolated antibody or antigen-binding fragment thereof of claim 6 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:280.

23. An isolated antibody or antigen-binding fragment thereof that binds to human MASP-3, comprising a heavy chain variable region comprising SEQ ID NO:254 or SEQ ID NO:255 and a light chain variable region comprising SEQ ID NO:256 or SEQ ID NO:280.

24. The isolated antibody or antigen-binding fragment thereof of claim 23 , wherein the heavy chain variable region comprises SEQ ID NO:254 and the light chain variable region comprises SEQ ID NO:256.

25. The isolated antibody or antigen-binding fragment thereof of claim 23 , wherein the heavy chain variable region comprises SEQ ID NO:255 and the light chain variable region comprises SEQ ID NO:256.

26. The isolated antibody or antigen-binding fragment thereof of claim 23 , wherein the heavy chain variable region comprises SEQ 1D NO:254 and the light chain variable region comprises SEQ ID NO: 280.

27. The isolated antibody or antigen-binding fragment thereof of claim 23 , wherein the heavy chain variable region comprises SEQ ID NO:255 and the light chain variable region comprises SEQ ID NO: 280.

28. The isolated antibody of claim 23 , wherein the antibody is selected from the group consisting of a single chain antibody, an ScFv, a Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, a univalent antibody lacking a hinge region and a whole antibody.

29. The isolated antibody of claim 23 , further comprising an immunoglobulin constant region.

30. A composition comprising the antibody or antigen-binding fragment of any of claims 1 , 6 or 22 and a pharmaceutically acceptable excipient.

Assignments (8)

Continuity (4)